Compare SGLD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SGLD | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 54.5M |
| IPO Year | 2009 | 2024 |
| Metric | SGLD | BOLD |
|---|---|---|
| Price | $3.21 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 115.4K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.96 |
| 52 Week High | $5.45 | $3.16 |
| Indicator | SGLD | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 53.40 |
| Support Level | N/A | $2.43 |
| Resistance Level | $3.70 | $2.65 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 7.71 | 56.82 |
Scorpio Gold Corp is a company that is engaged in mineral exploitation, exploration, and development in the United States. It holds an interest in the Mineral Ridge gold project, which is located in the northwest of the town of Silver Peak and west of Tonopah in Esmeralda County, Nevada. Its other project includes the Goldwedge property, which is located north-northeast of the town of Tonopah within the Manhattan Mining District of south-central Nevada.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.